0001513363 2025-10-01 2025-10-01 iso4217:USD false 0001513363 8-K 2025-10-01 Fidus Investment Corporation MD 814-00861 27-5017321 1603 Orrington Avenue Suite 1005 Evanston IL 60201 847 859-3940 false false false false Common Stock, par value $0.001 per share FDUS NASDAQ false <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October 1, 2025, Fidus Investment Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) by and among the Company and Fidus Investment Advisors, LLC (the “Adviser”), on the one hand, and Raymond James &amp; Associates, Inc. and ING Financial Markets LLC, as representatives of the several underwriters named in Exhibit A thereto, on the other hand, in connection with the issuance and sale of an additional $100.0 million in aggregate principal amount of the Company’s 6.750% Notes due 2030 (the “New 2030 Notes” and the issuance and sale thereof, the “Offering”). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement includes customary representations, warranties, and covenants by the Company and the Adviser. It also provides for customary indemnification by each of the Company, the Adviser, and the underwriters against certain liabilities and customary contribution provisions in respect of those liabilities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement, which is filed as an exhibit hereto and incorporated by reference herein. </div> 100000000 6.750% Notes due 2030 The Underwriting Agreement includes customary representations, warranties, and covenants by the Company and the Adviser. It also provides for customary indemnification by each of the Company, the Adviser, and the underwriters against certain liabilities and customary contribution provisions in respect of those liabilities. On October 3, 2025, the Company caused notices to be issued to the holders of its 4.75% Notes due 2026 (CUSIP No. 316500 AB3) (the “2026 Notes”) regarding the Company’s exercise of its option to redeem, in full, $100.0 million in aggregate principal amount of the issued and outstanding 2026 Notes, pursuant to Section 1104 of the Base Indenture and Section 1.01(h) of the Fourth Supplemental Indenture, dated as of December 23, 2020, by and between the Company and the Trustee. The Company will redeem $100.0 million in aggregate principal amount of the issued and outstanding 2026 Notes on November 3, 2025 (the “Redemption Date”). The redemption price for the 2026 Notes equals 100% of the $100.0 million aggregate principal amount of the 2026 Notes being redeemed on the Redemption Date, plus accrued and unpaid interest to, but excluding, the Redemption Date. A copy of the notice of redemption of the 2026 Notes is filed as Exhibit 99.1 hereto and incorporated by reference herein. 4.75% Notes due 2026